Recommendations for the use of Haemophilus influenzae type b vaccines among children in the United States

Pediatric Annals

Volumn 26, Issue 6, 1997, Pages 361-365

  Bisgard, Kristine M ^a   Wenger, Jay D ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; DRUG USE; HUMAN; INFECTION PREVENTION; REVIEW; TREATMENT PLANNING; UNITED STATES;

EID: 0031471425     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19970601-05     Document Type: Review

References (27)

1. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 1985;253:521-529.
2. Ward J, Leiberman JM, Cochi SL. Haemophilus influenzae vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:337-386.
3. Centers for Disease Control (CDC). Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis and Haemophilus type b vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 1993;42(RR-13):1-15.
4. Centers for Disease Control and Prevention (CDC). Progress towards elimination of Haemophilus influenzas type b disease among infants and children - United States, 1987-1995. MMWR. 1996;45:901-906.
5. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-226.
6. Committee on Infectious Diseases, American Academy of Pediatrics. In: Peter G, Halsey NA, Marcuse EK, Pickering LK, eds. 1994 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, Ill: AAP; 1994:203-216.
7. Robbins JB, Schneerson R, Anderson P, Smith DH. Prevention of systemic infections especially meningitis, caused by Haemophilus influenzae type b: impact on public health and implications for other polysaccharide-based vaccines. JAMA. 1996;276:1181-1185.
8. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infants. N Engl J Med. 1987;317:717-722.
9. Ward J, Brenneman G, Letson GW, Heyward WL, Alaska H influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med. 1990;323:1381-1387.
10. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324:1767-1772.
11. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 children. Pediatr Infect Dis J. 1991;10:97-104.
12. Eskola J, Peltola H, Takala A, Palmgren J, Makela PH. Protective efficacy of the Haemophilus influenzae type b conjugate vaccine HbOC in Finnish infants. In: Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Atlanta, GA), American Society for Microbiology; Washington, DC; 1990. Abstract No. 60.
13. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics. 1993;92:272-279.
14. Booy R, Moxon ER, Macfariane JA, Mayon-White RT, Slack MPE. Efficacy of Haemophilus influenzae type b conjugate vaccine in Oxford region. Lancet. 1992:340:847.
15. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr. 1992;121:355-362.
16. Kaythty H, Peltola H, Karanko V, Makala PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.
17. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 1992;120:184-189.
18. Bulkow OR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska native infants. Pediatr Infect Dis J. 1993;12:484-492.
19. Granoff DM, Anderson EL, Osterhom MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992;121:187-194.
20. Reid R, Santosham M, Croll J, Thompson C, Newcomer W, Siber GR. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs HbOC vaccine. Pediatr Infect Dis J. 1993;12:812-815.
21. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA. 1995;272:849-853.
22. Greenberg DP, Lieberman JM, Marcy M, et al. Enhanced antibody responses in infants given different sequences of heterogenous Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126:206-211.
23. Goldblatt D, Fairley CK, Cartwright K, Miller E. Interchangeability of Haemophilus influenzae type b vaccines during primary immunization of infants. BMJ. 1996;312:817-818.
24. Bewley KM, Schwab JG, Ballanco GA, Daum RS. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen. Pediatrics. 1996;98:898-904.
25. Centers for Disease Control (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1994;43(RR-1):18,31.
26. CDC. Notice to readers: recommended childhood immunization schedule -United States, 1997. MMWR. 1997;46:35-40.
27. Eskola J. Analysis of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis combination vaccines. J Infect Dis. 1996; 174(suppl 3):S302-S305.